Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.21% |
| 2 | Technology | 12.9% |
| 3 | Consumer Discretionary | 10.45% |
| 4 | Financials | 8.48% |
| 5 | Industrials | 7.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3051
Vanguard Industrials ETF
VIS
$8.5B
| $323K | ﹤0.01% |
2,100
-500
| -19% | -$75.2K |
|
3052
Enlivex Ltd
ENLV
$31M
| $322K | ﹤0.01% |
2,559
+973
| +61% | +$129K |
|
3053
QuinStreet
QNST
$1.19B
| $322K | ﹤0.01% |
+21,000
| New | +$299K |
|
|
CYAN
3054
DELISTED
Cyanotech Corp
CYAN
| $322K | ﹤0.01% |
140,400
+2,300
| +2% | +$5.45K |
|
|
UFAB
3055
DELISTED
Unique Fabricating, Inc.
UFAB
| $321K | ﹤0.01% |
83,199
+23,000
| +38% | +$73K |
|
3056
PDS Biotechnology
PDSB
$13M
| $319K | ﹤0.01% |
120,269
+28,700
| +31% | +$81.8K |
|
|
BNSO
3057
DELISTED
Bonso Electronic International
BNSO
| $319K | ﹤0.01% |
138,900
+600
| +0.4% | +$1.41K |
|
|
OPRA
3058
Opera Ltd
OPRA
$1.78B
| $318K | ﹤0.01% |
34,423
-2,877
| -8% | -$28.2K |
|
|
FSTX
3059
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
| $317K | ﹤0.01% |
50,233
+12,783
| +34% | +$162K |
|
3060
Business First Bancshares
BFST
$1.05B
| $314K | ﹤0.01% |
12,606
+4,402
| +54% | +$108K |
|
3061
Highway Holdings
HIHO
$5.27M
| $314K | ﹤0.01% |
193,627
+6,000
| +3% | +$10.2K |
|
|
MNTX
3062
DELISTED
Manitex International, Inc.
MNTX
| $314K | ﹤0.01% |
52,699
+14,659
| +39% | +$83.6K |
|
3063
Corporacion America
CAAP
$6.43B
| $313K | ﹤0.01% |
+52,100
| New | +$233K |
|
3064
Arcosa
ACA
$7.12B
| $312K | ﹤0.01% |
7,000
-1,200
| -15% | -$46.1K |
|
|
OSN
3065
DELISTED
Ossen Innovation Co., Ltd.
OSN
| $312K | ﹤0.01% |
101,207
+59,401
| +142% | +$210K |
|
|
SORL
3066
DELISTED
SORL Auto Parts, Inc.
SORL
| $307K | ﹤0.01% |
+69,087
| New | +$252K |
|
|
PLXP
3067
DELISTED
PLx Pharma Inc. Common Stock
PLXP
| $306K | ﹤0.01% |
70,111
+1,400
| +2% | +$6.58K |
|
3068
Summit Therapeutics
SMMT
$11.2B
| $304K | ﹤0.01% |
189,834
+77,728
| +69% | +$125K |
|
|
AKTX
3069
Akari Therapeutics
AKTX
$12.6M
| $301K | ﹤0.01% |
215
+45
| +26% | +$66.3K |
|
3070
First Trust Exchange-Traded Fund VI Multi-Asset Diversified Income Index Fund
MDIV
$432M
| $301K | ﹤0.01% |
+16,000
| New | +$295K |
|
3071
Ternium
TX
$10.8B
| $301K | ﹤0.01% |
13,700
-237,800
| -95% | -$4.84M |
|
3072
Futu Holdings
FUTU
$14.7B
| $298K | ﹤0.01% |
+28,896
| New | +$306K |
|
|
EVOP
3073
DELISTED
EVO Payments, Inc. Class A Common Stock
EVOP
| $298K | ﹤0.01% |
11,300
-11,200
| -50% | -$308K |
|
3074
Greenlight Captial
GLRE
$505M
| $295K | ﹤0.01% |
29,200
+9,814
| +51% | +$102K |
|
3075
Theriva Biologics
TOVX
$10.6M
| $295K | ﹤0.01% |
2,327
+321
| +16% | +$34.2K |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.